Jelle Koopsen

Jelle Koopsen

Auto-generated profile, based on publicly available information

Jelle Koopsen

Department of Infectious Diseases, Public Health Service Amsterdam (GGD Amsterdam), Amsterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2019 in Epidemiology and Infection
Verified
Journal Article
Open access
PDF file
JKJ. Koopsen
J. Koopsen
JSJ. E. van Steenbergen
J. E. van Steenbergen
JRJ. H. Richardus
J. H. Richardus
MPM. Prins
M. Prins
ECE. L. M. Op de Coul
E. L. M. Op de Coul
IVI. K. Veldhuijzen
I. K. Veldhuijzen
Chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are usually asymptomatic for decades, thus targeted screening can prevent liver disease by timely diagnosis and linkage to care. More robust estimates of chronic HBV and HCV infections in the general population and risk groups are needed. Using a modified workbook method, the total number of ever chronically infected individuals in the Netherlands in 2016 was determined using population size and prevalence estimates from studies in the general and high-risk population. The estimated 2016 chronic HBV infection prevalence is 0.34% (low 0.22%, high 0.47%), corresponding to approximately 49 000 (low 31 000, high 66 000) HBV-infected individuals aged 15 years and older. The estimated ever-chronic HCV infection prevalence is 0.16% (low 0.06%, high 0.27%), corresponding to approximately 23 000 (low 8000, high 38 000) ever-chronic HCV-infected individuals. The prevalence of chronic HBV and HCV infections in the Netherlands is low. First-generation migrants account for most infections with 81% and 60% of chronic HBV and HCV infections, respectively. However, about one-fifth of HCV infections is found in the general population at low risk. This method can serve as an example for countries in need of more accurate prevalence estimates, to help the design and evaluation of prevention and control policies.

8 November 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ASAnita Suijkerbuijk
Anita Suijkerbuijk
AHAlbert Jan Van Hoek
Albert Jan Van Hoek
JKJelle Koopsen
Jelle Koopsen
RMRobert A De Man
Robert A De Man
MMMarie-Josee J Mangen
Marie-Josee J Mangen
IVIrene K Veldhuijzen
Irene K Veldhuijzen
Chronic infection with hepatitis B or C virus (HBV/HCV) can progress to cirrhosis, liver cancer, and even death. In a low endemic country as the Netherlands, migrants are a key risk group and could benefit from early diagnosis and antiviral treatment. We assessed the cost-effectiveness of screening foreign-born migrants for chronic HBV and/or HCV using a societal perspective. The cost-effectiveness was evaluated using a Markov model. Estimates on prevalence, screening programme costs, participation and treatment uptake, transition probabilities, healthcare costs, productivity losses and utilities were derived from the literature. The cost per Quality Adjusted Life Year (QALY) gained was estimated and sensitivity analyses were performed. For most migrant groups with an expected high number of chronically infected cases in the Netherlands combined screening is cost-effective, with incremental cost-effectiveness ratios (ICERs) ranging from €4,962/QALY gained for migrants originating from the Former Soviet Union and Vietnam to €9,375/QALY gained for Polish migrants. HBV and HCV screening proved to be cost-effective for migrants from countries with chronic HBV or HCV prevalence of ≥0.41% and ≥0.22%, with ICERs below the Dutch cost-effectiveness reference value of €20,000/QALY gained. Sensitivity analysis showed that treatment costs influenced the ICER for both infections. For most migrant populations in a low-endemic country offering combined HBV and HCV screening is cost-effective. Implementation of targeted HBV and HCV screening programmes to increase early diagnosis and treatment is important to reduce the burden of chronic hepatitis B and C among migrants.

1 July 2016 in Journal of Structural Biology
Verified
Journal Article
Closed access
BHBas Ten Harkel
Bas Ten Harkel
JKJelle Koopsen
Jelle Koopsen
SPSander M. van Putten
Sander M. van Putten
HVHenk van Veen
Henk van Veen
DPDaisy I. Picavet
Daisy I. Picavet
VEVincent Everts
Vincent Everts

8 December 2020 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
PDF file
JKJelle Koopsen
Jelle Koopsen
EPEdyth Parker
Edyth Parker
AHAlvin X Han
Alvin X Han
TLThijs van de Laar
Thijs van de Laar
CRColin Russell
Colin Russell
JSJanke Schinkel
Janke Schinkel
Background: It is unclear whether unrestricted access and high uptake of direct-acting antivirals (DAAs) is sufficient to eliminate hepatitis C virus (HCV) in high-risk populations such as men who have sex with men (MSM). This study presents historic trends and current dynamics of HCV transmission among MSM in Amsterdam based on sequence data collected between 1994 and 2019. Methods: Hypervariable region 1 sequences of 232 primary HCV infections and 56 reinfections were obtained from 244 MSM in care in Amsterdam. Maximum-likelihood phylogenies were constructed for HCV genotypes separately, and time-scaled phylogenies were constructed using a Bayesian coalescent approach. Transmission clusters were determined by Phydelity and trends in the proportion of unclustered sequences over time were evaluated using logistic regression. Results: Seventy-six percent (218/288) of sequences were part of 21 transmission clusters and 13 transmission pairs. Transmission cluster sizes ranged from 3 to 44 sequences. Most clusters were introduced between the late 1990s and early 2010s and no new clusters were introduced after 2012. The proportion of unclustered sequences of subtype 1a, the most prevalent subtype in this population, fluctuated between 0% and 20% in 2009–2012, after which an increase occurred from 0% in 2012 to 50% in 2018. Conclusions: The proportion of external introductions of HCV infections among MSM in Amsterdam has recently increased, coinciding with high DAA uptake. Frequent international transmission events will likely complicate local microelimination efforts. Therefore, international collaboration combined with international scale-up of prevention, testing, and treatment of HCV infections (including reinfections) is warranted, in particular for local microelimination efforts.

1 May 2022 in Emerging Infectious Diseases
Verified
Journal Article
Open access
JKJelle Koopsen
Jelle Koopsen
CECatharina E. van Ewijk
Catharina E. van Ewijk
RBRoisin Bavalia
Roisin Bavalia
ACAkke Cornelissen
Akke Cornelissen
SBSylvia M. Bruisten
Sylvia M. Bruisten
OCon behalf of the ARGOS consortium
on behalf of the ARGOS consortium
SARS-CoV-2 Delta Variant Superspreading Event

16 June 2023 in The Lancet Microbe
Verified
Journal Article
Open access
JKJelle Koopsen
Jelle Koopsen
GMGail Matthews
Gail Matthews
JRJuergen Rockstroh
Juergen Rockstroh
TATanya L Applegate
Tanya L Applegate
SBSanjay Bhagani
Sanjay Bhagani
EWEric Witele
Eric Witele
Microelimination of the hepatitis C virus (HCV) among men who have sex with men (MSM) could be complicated by continuous external introductions and the emergence of phylogenetic clusters harbouring clinically significant resistance-associated substitutions (RAS). To investigate international clustering and the prevalence and transmission of RAS, we aimed to analyse whole-genome HCV sequences from MSM with a recently acquired infection who participated in a large, international HCV treatment trial. For this whole-genome analysis, we obtained HCV sequences from 128 MSM who had acquired HCV within the past 12 months and were participating in the REACT trial. The participants from whom sequences were obtained were recruited at 24 sites in eight countries. We inferred maximum-likelihood phylogenies and identified transmission clusters for HCV genotypes separately. We constructed time-scaled phylogenies to estimate cluster introduction dates and used a Bayesian Skygrid approach to estimate the effective population size over the past 50 years. We calculated the prevalence of RAS and the extent of RAS transmission in the study population. The majority of recent HCV infections were part of international networks that arose in the late 1990s and early 2000s. Sequences obtained in the same country clustered frequently, and in 36% of subclusters since 2015 we found evidence of international transmission. European MSM were more likely than non-European MSM to be in a cluster (odds ratio 11·9 [95% CI 3·6-43·4], p<0·0001). The effective population size decreased rapidly since around 2015 in Europe. RAS associated with substantially diminished cure rates were infrequently detected and transmission of highly resistant viruses was not observed. Despite antiviral treatment becoming widely available, international transmission of HCV among MSM has still occurred over the past 8 years, which could complicate microelimination of the virus in this population. RAS-enriched clusters and widespread RAS transmission are currently not a threat to elimination goals. These findings support an international approach for HCV microelimination among MSM. National Institutes of Health and Dr. C.J. Vaillant Fonds.